Emcure wins dismissal of US lawsuit over COVID vaccine trade secrets

Representatives for HDT did not immediately respond to a request for comment. A spokesperson for Emcure said on Tuesday morning that the ruling "vindicates our stand."

Seattle-based HDT sued Emcure last year. It said in the lawsuit that it was developing a self-amplyifing RNA (saRNA) shot for COVID-19 that is "safer, cheaper, more portable, and likely more effective" than existing mRNA vaccine technology.

The lawsuit said that HDT licensed its technology to Emcure subsidiary Gennova Biopharmaceuticals to develop and sell the vaccine in India. HDT accused Gennova of later claiming the vaccine "as its own," applying for two Indian patents on HDT's technology and touting the "indigenously developed" shots in regulatory filings.

HDT's lawsuit said that Gennova refused to pay royalties and broke their licensing agreement, requesting at least $950 million in monetary damages. It has also filed a related complaint with the London Court of International Arbitration.

Gennova's COVID-19 vaccine was approved for emergency use by the Indian government last June.

Emcure argued in September that the court lacked jurisdiction over the company because it has no business presence in the United States, and that it and Gennova are "unquestionably distinct separate entities."

"This is an illegitimate lawsuit brought by a company using litigation to compensate for its business shortcomings," Emcure said.

The case is HDT Bio Corp v. Emcure Pharmaceuticals Ltd, U.S. District Court for the District of Washington, No. 2:22-cv-00334.

For HDT: Peter Stris, Dana Berkowitz, Kenneth Halpern and John Stokes of Stris & Maher

For Emcure: James Sanders, Amanda Beane and Eric Wolff of Perkins Coie